STOCK TITAN
  1. Home
  2. Sec-filings
  3. FLGT
  4. [Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Fulgent Genetics (FLGT) COO receives stock awards and tax withholdings

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Fulgent Genetics, Inc. President and COO Jian Xie reported a mix of stock awards and tax-related share withholdings. On February 24, 2026, he acquired several blocks of common stock at no cost through vested performance-based restricted stock units granted in 2023, 2024, and 2025.

He also received a new grant of 31,962 restricted stock units that vest over three years starting 12 months after March 1, 2026. Shares totaling 3,163, 8,254, 14,751 and 655 were withheld at prices around $23 per share to satisfy tax obligations. Additional indirect holdings are reported in The Hsieh Family Dynasty Trust, where Xie notes only a pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Xie Jian
Role President and COO
Type Security Shares Price Value
Grant/Award Common Stock 5,862 $0.00 --
Grant/Award Common Stock 15,299 $0.00 --
Grant/Award Common Stock 27,341 $0.00 --
Tax Withholding Common Stock 3,163 $23.09 $73K
Tax Withholding Common Stock 8,254 $23.09 $191K
Tax Withholding Common Stock 14,751 $23.09 $341K
Grant/Award Common Stock 31,962 $0.00 --
Tax Withholding Common Stock 655 $23.01 $15K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 337,245 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)
Footnotes (1)
  1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025. Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Xie Jian
(Last) (First) (Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE
(Street)
EL MONTE CA 91731
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/23/2026 F 655(1) D $23.01 331,383 D
Common Stock 02/24/2026 A 5,862(2) A $0 337,245 D
Common Stock 02/24/2026 A 15,299(3) A $0 352,544 D
Common Stock 02/24/2026 A 27,341(4) A $0 379,885 D
Common Stock 02/24/2026 F 3,163(5) D $23.09 376,722 D
Common Stock 02/24/2026 F 8,254(6) D $23.09 368,468 D
Common Stock 02/24/2026 F 14,751(7) D $23.09 353,717 D
Common Stock 02/24/2026 A 31,962(8) A $0 385,679 D
Common Stock 220,816 I By Trust(9)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.
2. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023.
3. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024.
4. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025.
5. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023.
6. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024.
7. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025.
8. Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.
9. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
/s/ Paul Kim as Attorney-in-Fact 02/25/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Fulgent Genetics (FLGT) report for Jian Xie?

Fulgent Genetics reported that President and COO Jian Xie received multiple stock awards and had shares withheld for taxes. The filing covers performance-based restricted stock units that vested and a new three-year restricted stock unit grant, plus related tax-withholding share dispositions.

How many Fulgent Genetics shares were granted to Jian Xie in the latest awards?

Jian Xie received several stock awards, including a new grant of 31,962 restricted stock units. Additional shares came from performance-based units vesting in blocks of 5,862, 15,299, and 27,341 shares tied to milestones from 2023, 2024, and 2025 grants, all at no cash cost.

How many Fulgent Genetics shares were withheld to cover Jian Xie’s taxes?

Shares were withheld to cover Jian Xie’s tax obligations upon vesting of restricted stock units. Withholdings totaled 3,163, 8,254, 14,751, and 655 shares at prices around $23 per share, reflecting non-market tax-withholding dispositions rather than open-market sales of Fulgent Genetics stock.

What are the vesting terms of Jian Xie’s new restricted stock units at Fulgent Genetics?

The new restricted stock units for Jian Xie vest over three years. One-third vests 12 months after March 1, 2026, and one-twelfth vests every three months over the following 24 months, contingent on his continued service with Fulgent Genetics on each vesting date.

What performance-based stock units vested for Jian Xie at Fulgent Genetics?

Performance-based restricted stock units granted on February 23, 2023, February 26, 2024, and February 25, 2025 vested after meeting defined performance milestones. These vestings delivered share blocks, which were partly offset by share withholdings to satisfy the related tax withholding obligations for Jian Xie.

How are Jian Xie’s indirect Fulgent Genetics holdings structured?

Indirect holdings are reported through The Hsieh Family Dynasty Trust dated January 27, 2010. Jian Xie serves on the trust’s investment committee and disclaims beneficial ownership of its Fulgent Genetics securities, except to the extent of any pecuniary interest he may have in those holdings.